title: Advances in the management of MS symptoms: recently proposed clinical management algorithms.
abstract: Guidelines from both the German and Spanish Neurology Societies for managing patients with multiple sclerosis (MS) spasticity emphasize the importance of setting clear objectives and use evidence levels and grades to support their recommendations. Swedish guidelines for MS spasticity also reflect the need to establish treatment aims and recommend use of validated scales to measure symptom changes. Treatment of generalized MS spasticity, beyond physiotherapy, tends to begin with baclofen, tizanidine and/or diazepam, adding Sativex (THC:CBD) oromucosal spray for moderate-to-severe cases. The European Federation of Neurological Societies/European Academy of Neurology Taskforce on Spasticity in Multiple Sclerosis is currently reviewing the literature supporting the pharmacological treatment of MS spasticity and aims to publish recommendations in the near future to guide clinicians in their treatment choices.
authors.affiliation: Department of Neurology, University of Lille, Hôpital Roger Salengro, CHU de Lille, Lille cedex 59037, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Vermersch
mesh_terms: D000465:Algorithms; D002185:Cannabidiol; D002986:Clinical Trials as Topic; D019468:Disease Management; D013759:Dronabinol; D004338:Drug Combinations; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000628:therapy*; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology; D010936:Plant Extracts / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D010936:Plant Extracts; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols
keywords: Sativex; THC:CBD oromucosal spray; algorithms; multiple sclerosis; review; spasticity management guidelines